<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821691</url>
  </required_header>
  <id_info>
    <org_study_id>01-APN-08</org_study_id>
    <nct_id>NCT00821691</nct_id>
  </id_info>
  <brief_title>Action of Amantadine on Post-Stroke Aphasic Patients</brief_title>
  <acronym>CELIC-1</acronym>
  <official_title>Action of the Amantadine on Post Stroke Aphasic Patients' Language and Communication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to test the action of the amantadine, as DOPA-agonist, in a
      double blind cross-over trial, amantadine / placebo, on the verbal fluency of chronic post
      stroke aphasic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In France, there are around 30000 aphasic patients. The actual taking care of these patients
      after stroke includes the treatment of acute stage in stroke unit, followed by rehabilitation
      program. However, most non fluent aphasic patients remain chronically handicapped despite of
      intensive logopedic training.

      The objective of this clinical project is to test the action of pharmacologic agents on
      verbal fluency of aphasic patients victims of cerebral infarctions. Only a few studies have
      been done with various pharmacologic agents, and although the results were not clearly
      conclusive, they were sufficiently positive for suggesting to launch a well controlled
      randomized cross-over study.

      Then the objective of study is to test the action of the amantadine, as DOPA-agonist, in a
      double blind cross-over trial, amantadine / placebo, on the verbal fluency of chronic post
      stroke aphasic patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirm that the possibility of significantly improving the verbal fluency and communication of patients with &quot;not fluent&quot; aphasia at the chronic stage when logopedic rehabilitation is &quot;stabilized&quot; (&gt; 6months).</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Codify a drug test to be included in the&quot; recommendations &quot;to take care of these patients</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish correlations between clinical, neuroradiological lesions and pharmacological responses, as to argue in favour of long-term treatment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify extra linguistic components of communication influenced by amantadine</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Amantadin - Placebo: 5 amantadin caps - 4 days wash out - 5 placebo caps
5 amantadin caps (100mg); 2 caps a day during 3 days; after wash out period (4 days): 5 placebo caps (2 caps a day during 3 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo - Amantadin: 5 placebo caps - 4 days wash out - 5 amantadin caps
5 placebo caps: 2 caps a day during 3 days after wash out period (4 days): 5 amantadin caps(100mg) (2 caps a day during 3 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadin</intervention_name>
    <description>Amantadin caps</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo caps</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RANKIN &lt; 3

          -  &gt; 18 years and &lt; 75

          -  francophone

          -  within cognitive deficit known before stroke

          -  stroke, single in sylvian artery area

          -  aphasia &quot; non fluent &quot; following a stroke

          -  stroke &gt; six month

          -  stable treatment

        Exclusion Criteria:

          -  RANKIN &gt; 3

          -  non francophone

          -  do not read nor write

          -  many stroke - against indication

          -  participated in another clinical trial

          -  deaf or blind

          -  intercurrent disease

          -  new treatment (&lt; 2 months) cognitive

          -  pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcel CHATEL, MDPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital of Nice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hélène MAHAGNE, PH</last_name>
    <role>Study Director</role>
    <affiliation>University hospital of Nice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvain LACHAUD, PH</last_name>
    <role>Study Director</role>
    <affiliation>University hospital of Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Saint Pierre La Réunion</name>
      <address>
        <city>Saint Pierre</city>
        <state>Ile de La Réunion</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>January 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2009</study_first_posted>
  <last_update_submitted>April 18, 2014</last_update_submitted>
  <last_update_submitted_qc>April 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cerebral infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

